<DOC>
	<DOCNO>NCT00343291</DOCNO>
	<brief_summary>The primary objective study determine progression free survival patient stage IIIb/IV non-small cell lung cancer ( NSCLC ) treat dual agent monoclonal antibody therapy consist cetuximab bevacizumab combination two different regimen paclitaxel carboplatin chemotherapy .</brief_summary>
	<brief_title>A Study Cetuximab Bevacizumab Combination With Paclitaxel Carboplatin Stage IIIb/IV NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The patient histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , except squamous cell carcinoma . Mixed tumor categorize predominant cell type , presence small cell lung cancer element make patient ineligible . Cytologic histologic element establish metastatic tumor aspirate biopsy . The patient advance NSCLC ( Stage IIIB malignant pleural effusion Stage IV recurrent disease ) . Patients must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) . The patient 's Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . The patient adequate hematologic function define Absolute Neutrophil Count great equal 1500/mm³ , hemoglobin great equal 9 gm/dL , platelet count great equal 100,000/mm³ obtain within 2 week prior first dose study medication . The patient adequate hepatic function define total bilirubin great equal 1.5 mg/dL transaminase alkaline phosphatase less equal 5 x Upper Limit Normal ( ULN ) obtain within 2 week prior first dose study medication . The patient adequate renal function define serum creatinine less equal 1.5 x ULN calculate creatinine clearance ( CrCl ) &gt; 60 mL/minute , urine dipstick proteinuria &lt; 1+ ( ie , either 0 trace ) obtain within 2 week prior first dose study medication . If urine dipstick great equal 1+ , 24hour urine protein must demonstrate &lt; 500 mg protein 24 hour allow participation study . The patient adequate coagulation function define International Normalized Ratio less equal 1.5 Prothrombin time partial thromboplastin time le equal ULN obtain within 2 week prior first dose study medication . The patient , woman childbearing potential , agree use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study . If male sexually active , patient agrees use effective contraception . The patient know Central Nervous System metastases . A head compute tomography ( CT ) require within 4 week prior first dose study medication ( magnetic resonance imago [ MRIs ] also acceptable ) . The patient receive prior cetuximab therapy . The patient receive prior bevacizumab therapy . The patient receive prior systemic chemotherapy radiation therapy time lung cancer . Any concurrent malignancy basal cell skin cancer , carcinoma situ cervix . Patients adequately treat cancer histology diseasefree 3 year prior first treatment dose eligible . Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy . The patient ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The patient history thrombotic hemorrhagic disorder . The patient uncontrolled hypertension ( &gt; 150/100 mmHg ) standard regimen antihypertensive therapy . The patient receive chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory agent know inhibit platelet function . The patient receive treatment dipyridamole ( Persantine® ) , ticlopidine ( Ticlid® ) , clopidogrel ( Plavix® ) /or cilostazol ( Pletal® ) . The patient receive anticoagulation therapy . Prophylactic anticoagulation venous access device allow . Caution take treat patient low dose heparin low molecular weight heparin deep vein thrombosis ( DVT ) prophylaxis treatment bevacizumab may increase risk bleeding . Patients history gross hemoptysis ( define bright red blood great equal ½ teaspoon ) . The patient serious nonhealing wound ulcer , bone fracture , major surgical procedure within 30 day prior first dose study medication . Elective plan major surgery perform course trial . The patient preexist neuropathy &gt; grade 1 . The patient , woman , pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Malignant pleural effusion</keyword>
</DOC>